“The doctors and staff at Atlantic Retina Center are excellent. Dr Rial is thorough and tells you about the real deal in a way you can understand it. I couldn't ask for better treatment.”
Can AMD Be Reversed?
Current Treatments and What They Achieve
Our team uses a full range of proven treatments to manage AMD at every stage. What each treatment can accomplish depends on the type and severity of AMD, as well as how quickly care begins.
Anti-VEGF injections are the primary treatment for wet AMD. A specialist injects medication directly into the vitreous (the gel-filled interior of the eye) to block the proteins that drive abnormal blood vessel growth. Available options include bevacizumab (Avastin), ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo). Vabysmo works through a dual mechanism targeting both VEGF and a second pathway called angiopoietin-2, which can allow longer intervals between injections for some patients. Most patients treated with anti-VEGF either stabilize their vision or see measurable improvement.
Geographic atrophy is a late stage of dry AMD in which areas of the retina are permanently lost. Complement inhibitors target the immune pathway that drives ongoing inflammatory damage in these areas. Avacincaptad pegol (Izervay) is one FDA-approved option in this class. These treatments slow the rate at which geographic atrophy expands over time. They do not restore cells that have already been lost, but preserving surrounding tissue is still a meaningful goal.
Photobiomodulation is a light-based therapy that delivers specific wavelengths of light to the retina to support cellular function. An FDA-cleared photobiomodulation system became available for intermediate dry AMD, with clinical data showing that some patients experienced visual acuity improvement sustained over time. This represents one of the closest current options to functional vision improvement in dry AMD, though it is not appropriate for every patient and results vary. Ask your specialist whether this approach may be suitable for your situation.
Emerging Therapies That May Change the Outlook
The AMD treatment landscape is changing faster than at any previous point. Several research pathways are working toward true reversal of AMD damage, and some have reached encouraging early stages. None of the following are commercially available as of 2026, but they represent the clearest directions science is moving.
Gene therapy delivers genetic instructions directly into retinal cells, with the goal of producing a long-lasting therapeutic effect from a single treatment. Early-phase clinical trials for wet AMD have demonstrated that this approach is feasible. The aim is to reduce or eliminate the need for repeated injections over time. No gene therapy for AMD has received full FDA approval for commercial use yet, but multiple programs have reached advanced stages of clinical testing.
Researchers are investigating whether transplanting healthy retinal pigment epithelium cells can replace the ones AMD destroys. Early-phase trials have shown that this approach is biologically feasible, meaning transplanted cells can survive and integrate into the retina. If proven safe and effective in larger trials, this could become the first treatment capable of truly restoring lost retinal tissue. This work remains experimental and is not available outside of clinical research settings.
Mitochondria are the energy-producing structures inside cells, and dysfunction in retinal cell mitochondria is believed to play a role in AMD. Drugs that stabilize mitochondrial function, including compounds such as risuteganib and elamipretide, have shown early promise in clinical trials for intermediate dry AMD. Some early data suggests the possibility of partial vision recovery in certain patients. These compounds are not yet FDA-approved, but they represent a new direction that targets the underlying biology of retinal degeneration.
What You Can Do Right Now
While research advances, there are concrete steps you can take today to protect the vision you have and position yourself for the best outcomes from both current and future treatments.
Wet AMD is a medical urgency. The window for achieving the best visual outcomes with anti-VEGF treatment is narrow. If you notice sudden distortion, a new blank spot in the center of your vision, or rapid changes to your eyesight in one eye, contact a retinal specialist as soon as possible. Do not wait to see if symptoms improve on their own.
If you have intermediate dry AMD, AREDS 2 supplements are an evidence-based tool to help slow progression. Stopping smoking, following a diet rich in leafy greens and fish, and staying physically active all support retinal health. If geographic atrophy is present, ask your specialist whether you qualify for complement inhibitor therapy. These steps will not undo existing damage, but they can meaningfully slow the pace of future loss.
AMD treatment and monitoring are ongoing, not one-time events. Regular retinal imaging allows your specialist to catch any progression early and adjust your care plan accordingly. Staying in consistent follow-up also keeps you informed about clinical trials and newly approved therapies as they become available. The patients who benefit most from emerging treatments are often those who have maintained an active relationship with their specialist.
Frequently Asked Questions
These questions address the decisions and concerns patients often face when navigating an AMD diagnosis.
For most patients, wet AMD requires long-term management rather than a fixed course of treatment. Stopping injections without guidance from your specialist can allow abnormal vessel activity to resume, sometimes resulting in vision loss that is difficult or impossible to recover. Some patients on newer agents with longer dosing intervals are able to space treatments further apart over time, but the decision to reduce or pause treatment should always be made with your specialist based on your imaging and vision results.
No lifestyle change can restore retinal tissue that has already been lost. That said, lifestyle factors do influence the rate at which AMD progresses, and they matter most when started early. A Mediterranean-style diet, not smoking, controlling blood pressure, and maintaining a healthy weight all support the remaining retinal tissue you have. Think of these as tools for slowing the disease rather than reversing it.
No. Clinics offering stem cell treatments for AMD outside of approved clinical trials are a serious patient safety concern. Several patients have suffered severe and permanent vision loss after receiving unproven stem cell injections at unregulated facilities. If you are interested in stem cell research for AMD, ask your specialist about legitimate clinical trials, which are conducted under strict safety oversight.
Eligibility for AMD clinical trials depends on your AMD type, its stage, your treatment history, and other health factors. The best starting point is a conversation with your retinal specialist, who can review your imaging and advise you on trials that may be appropriate for your situation. Staying in regular follow-up is the most reliable way to remain aware of trials as they open, since eligibility windows can be narrow and enrollment is often limited.
Absolutely. Slowing progression preserves the functional vision you currently have, which directly affects your quality of life and independence. Every year that geographic atrophy expands more slowly is a year of better central vision. Slowing the disease also buys time for emerging therapies to become available, and the research pipeline for dry AMD is more active today than it has ever been.
Yes, if your specialist has recommended them. AREDS 2 supplements are designed to reduce the risk of progressing to more advanced stages of AMD, which means they protect vision you still have rather than restoring what is gone. If you are unsure whether your current supplement formula matches the studied AREDS 2 formulation, bring the bottle to your next appointment so your specialist can confirm it is appropriate for your stage of AMD.
See Our Team at Atlantic Retina Center
Our team at Atlantic Retina Center specializes exclusively in the retina, vitreous, and macula, and we are experienced in managing AMD at every stage. We use serial retinal imaging at every visit so we can track your disease over time and adjust your care plan the moment something changes. If you are living with AMD or have been told you are at risk, we encourage you to schedule a visit at one of our clinic offices serving the Eastern Shore of Maryland and central and southern Delaware.